Prothrombin concentrates, sometimes referred to as prothrombin complex concentrates (PCC), are clotting factor medicines. PCCs are used to treat people with haemophilia B, as well as those who lack these factors owing to other variables such warfarin medication. Since most of the production facilities for prothrombin complex concentrates are situated in these areas, North America and Western Europe are likely to be the leading markets for prothrombin complex concentrates.
Plasma is commonly used as a major precursor in the production of prothrombin complex concentrates, and in the past, third-party plasma sources were used. To lessen reliance on third-party sources, manufacturers are already creating their own plasma collecting banks. Since 2013, this trend has become more pronounced. The market's major companies, such as CSL Behring & Shire, have increased their emphasis on relying on their own plasma suppliers.
Patients with haemophilia B and other illnesses should go to compound pharmacies, retail pharmacies, and hospital pharmacies that provide prothrombin complex concentrates. In 2017, the hospital pharmacy sector of the prothrombin complex concentrates market accounted for more than 40% of total revenue. Over the projected period, the increased need for cost-effective diagnostic solutions is likely to boost the worldwide prothrombin complex concentrates market forward.
Read more @ https://cmiaspireblog.blogspot.com/2021/10/prothrombin-complex-concentrates-market.html
